title: [SERV clinical practice guidelines: management of retinal vein occlusion. Sociedad Española de Retina y Vitreo].
abstract: OBJECTIVE
  A guidelines for the management of retinal vein occlusion is presented. This is necessary because at this moment several therapeutic alternatives have been developed although their role is not yet sufficiently defined.
  
  
  METHODS
  Review of the literature for evidence published up to date. Relevant literature was identified and the level of evidence graded. Evidence was then assessed for consistency, applicability and clinical impact. The information was contrasted with those guides published in other countries.
  
  
  RESULTS
  Taking into account the different options of treatment that are currently used, several modes of action are suggested. The role of the various complementary examinations are discussed and it is recommended that criteria for the treatment are based on clinical, angiographic, and tomographic findings.
  
  
  CONCLUSIONS
  Although there is no overall consensus, these guidelines promote a good standard of clinical practise and provide an update of the management of retinal vein occlusion.
authors.affiliation: Complejo Hospitalario Universitario de Santiago de Compostela, Instituto Tecnológico de Oftalmología, Santiago de Compostela, España.
authors.forename: F
authors.initials: F
authors.lastname: Gómez-Ulla
authors.forename: M J
authors.initials: MJ
authors.lastname: Abraldes
authors.forename: E
authors.initials: E
authors.lastname: Basauri
authors.forename: M
authors.initials: M
authors.lastname: Fernández
authors.forename: A
authors.initials: A
authors.lastname: García-Layana
authors.forename: P
authors.initials: P
authors.lastname: Gili
authors.forename: J
authors.initials: J
authors.lastname: Montero
authors.forename: J
authors.initials: J
authors.lastname: Nadal
authors.forename: V
authors.initials: V
authors.lastname: Morales
authors.forename: M
authors.initials: M
authors.lastname: Saravia
authors.forename: F
authors.initials: F
authors.lastname: Cabrera
authors.forename: E
authors.initials: E
authors.lastname: Cervera
mesh_terms: D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D000368:Aged; D000369:Aged, 80 and over; D000465:Algorithms; D020533:Angiogenesis Inhibitors / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D002318:Cardiovascular Diseases / Q000150:complications; D003930:Diabetic Retinopathy / Q000175:diagnosis / Q000628:therapy; D019317:Evidence-Based Medicine; D005451:Fluorescein Angiography; D005902:Glaucoma, Open-Angle / Q000150:complications; D006401:Hematologic Agents / Q000627:therapeutic use; D006801:Humans; D017075:Laser Coagulation; D008028:Light Coagulation; D008269:Macular Edema / Q000150:complications / Q000601:surgery / Q000628:therapy; D008875:Middle Aged; D012170:Retinal Vein Occlusion / Q000175:diagnosis / Q000188:drug therapy / Q000209:etiology / Q000503:physiopathology / Q000601:surgery / Q000628:therapy*; D012307:Risk Factors; D019851:Thrombophilia / Q000150:complications; D041623:Tomography, Optical Coherence
chemical_list: D000305:Adrenal Cortex Hormones; D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D006401:Hematologic Agents; D000068258:Bevacizumab